Eli Lilly and Company
LLY
$1107.08
+0.45%
Eli Lilly and Company is a global pharmaceutical leader focused on developing and commercializing medicines in key therapeutic areas including neuroscience, cardiometabolic diseases, cancer, and immunology. The company is a dominant market leader, particularly in the burgeoning obesity and diabetes drug market with its blockbuster products Mounjaro and Zepbound, and maintains a strong portfolio in oncology and immunology. The current investor narrative is overwhelmingly centered on the company's explosive growth driven by its GLP-1/GIP agonists, with intense debate focusing on the sustainability of this growth against emerging competition, the potential for label expansions into new indications, and the company's strategic moves to diversify its pipeline through acquisitions in areas like infectious diseases.…
LLY
Eli Lilly and Company
$1107.08
Related headlines
Investment Opinion: Should I buy LLY Today?
Rating & Thesis: Hold. Eli Lilly is a phenomenal company executing exceptionally well, but its stock price already reflects perfection, trading at a premium valuation near its 52-week high with significant competitive clouds gathering, making the risk/reward balanced at current levels. This aligns with the overwhelmingly bullish analyst sentiment but acknowledges the high price of admission.
Supporting Evidence: The Hold rating is supported by four key data points: 1) The stock trades at a forward PE of 24.69x, a premium to the sector, justified by 42.56% YoY revenue growth but leaving no margin for error. 2) Analyst consensus implies ~43% upside to a $1,575 target, but this is predicated on flawless execution of high expectations. 3) Profitability is stellar with a net margin of 34.40% and expanding operating leverage. 4) However, the technical picture shows the stock at 93% of its 52-week range after a 39.94% annual gain, indicating limited near-term upside without a new catalyst.
Risks & Conditions: The two biggest risks are valuation compression from increased competition and a growth deceleration in its core franchise. This Hold rating would upgrade to a Buy if the forward PE compresses below 20x on a market pullback without a deterioration in the growth narrative, or if the company demonstrates durable competitive moats that dispel near-term threats. It would downgrade to a Sell if quarterly revenue growth decelerates meaningfully below 30% YoY or if operating margins contract. The stock is currently fairly valued relative to its own explosive growth but overvalued relative to traditional pharmaceutical peers, implying the market expects sustained blockbuster performance.
Sign up to view all
LLY 12-Month Price Forecast
The outlook for LLY is a high-stakes battle between phenomenal execution and a premium valuation vulnerable to competition. The base case (50% probability) of solid growth with moderated expectations is most likely, as some competitive encroachment is inevitable. The bull case requires the company to defy gravity and competition indefinitely, while the bear case, though lower probability, carries severe downside given the valuation altitude. The stance is neutral due to the balanced risk/reward; confidence is medium because the competitive landscape is rapidly evolving. We would upgrade to bullish on evidence of sustained pricing power and successful pipeline diversification, or downgrade to bearish on confirmation of market share loss or margin contraction.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Eli Lilly and Company's 12-month outlook, with a consensus price target around $1439.20 and implied upside of +30.0% versus the current price.
Average Target
$1439.20
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$886 - $1439
Analyst target range
Analyst coverage for Eli Lilly is robust, with 11 analysts providing estimates. The consensus sentiment is overwhelmingly bullish, as evidenced by recent institutional ratings which include multiple 'Buy' and 'Overweight' reiterations from major firms like JP Morgan, Morgan Stanley, and Deutsche Bank, with only a single 'Reduce' rating from HSBC. The average target price is implied through estimated metrics; the average EPS estimate for the forward period is $63.81, which, applied to the forward PE of 24.69x, suggests a consensus price target of approximately $1,575, implying significant upside of over 43% from the current price of ~$1,099. The target range, derived from estimated EPS, is wide, indicating some uncertainty about the precise growth trajectory. The low EPS estimate is $59.54, suggesting a price target around $1,470, while the high estimate is $69.53, implying a target near $1,716. The high target assumes flawless execution, continued demand outstripping supply for GLP-1 drugs, and successful pipeline advancements. The low target likely factors in risks like increased competition, pricing pressure, or slower-than-expected market penetration. The recent pattern of analyst actions shows a preponderance of reiterations, signaling strong conviction in the existing bullish thesis rather than a wave of new upgrades.
Bulls vs Bears: LLY Investment Factors
The bull case, centered on explosive revenue growth (42.56% YoY), expanding margins, and strong analyst conviction for 43% upside, currently holds stronger evidence due to the company's demonstrated execution. However, the bear case presents formidable risks, primarily the stock's premium valuation (46.76x trailing PE) at historical highs and intense competitive threats emerging in its core GLP-1 market. The single most important tension in the investment debate is whether Eli Lilly's current hyper-growth can be sustained long enough to justify its elevated multiples before competition erodes its market dominance and pricing power. The resolution of this tension will dictate whether the stock compounds gains or experiences a painful valuation compression.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue grew 42.56% YoY to $19.29B, driven by the Cardiometabolic segment ($13.18B). This growth rate dramatically outpaces the typical pharmaceutical sector, justifying a premium valuation.
- Net margin reached 34.40% in Q4 2025, with gross margin expanding to 85.05% from 82.54% in Q1 2025. This demonstrates powerful operating leverage as the company scales its blockbuster GLP-1 drugs.
- Strong Analyst Conviction & Upside: Analyst consensus implies a price target of ~$1,575 based on a forward PE of 24.69x and average EPS estimate of $63.81, representing over 43% upside from the current price of $1,098.57. The sentiment is overwhelmingly bullish with 11 analysts covering.
- Robust Cash Generation & Capital Efficiency: Trailing twelve-month free cash flow is $8.97B, supporting R&D, dividends, and buybacks. Return on Equity is an extraordinary 77.78%, indicating highly efficient use of shareholder capital despite a debt-to-equity ratio of 1.60.
Bearish
- Premium Valuation at Historical Highs: The trailing PE of 46.76x and forward PE of 24.69x are at a substantial premium to large-cap pharma peers. Trading at 93% of its 52-week high ($1,182.73), the stock has little room for multiple expansion and is highly sensitive to growth disappointments.
- Intensifying Competitive Threats: Recent news highlights significant competitive pressure from Pfizer's promising monthly-injection weight-loss drug and Novo Nordisk's successful Wegovy pill. Any market share loss or pricing pressure could severely impact the growth narrative underpinning the valuation.
- Revenue Concentration & Growth Dependency: The investment thesis is overwhelmingly dependent on the continued hyper-growth of Mounjaro and Zepbound. The Cardiometabolic segment constituted 68% of Q4 2025 revenue, creating outsized risk if demand slows or new competitors gain traction.
- Elevated Financial Leverage: A debt-to-equity ratio of 1.60 reflects strategic borrowing for growth but increases financial risk in a rising rate environment. While current cash flow is strong, significant debt servicing costs could pressure earnings if growth decelerates.
LLY Technical Analysis
The stock is in a sustained long-term uptrend, evidenced by a 1-year price change of +39.94%, significantly outperforming the broader market's 24.99% gain. As of the latest close of $1,098.57, the price sits approximately 93% of its 52-week range ($623.78 to $1,182.73), indicating it is trading near its recent highs, which reflects strong investor momentum but also suggests potential overextension and vulnerability to profit-taking. The stock has experienced significant volatility within this uptrend, with a maximum drawdown of -23.64% over the observed period, highlighting the sharp corrections that have punctuated its rise. Recent short-term momentum is positive but shows signs of consolidation after a strong run. The 1-month price change is +7.55%, outpacing the SPY's +0.74%, and the 3-month change is +21.16%, also beating the market's +15.14%. However, the 6-month change of +2.53% lags the SPY's +9.72%, indicating the stock experienced a significant correction in the first quarter of 2026 before its recent recovery. This divergence suggests the longer-term uptrend remains intact, with the recent 3-month surge representing a recovery from a deep pullback rather than a new acceleration. Key technical support is anchored at the 52-week low of $623.78, while immediate resistance is at the 52-week high of $1,182.73. A decisive breakout above $1,182.73 would signal a resumption of the primary bull trend and likely target new highs, while a breakdown below the recent March lows near $878 could indicate a deeper correction is underway. The stock's beta of 0.517 indicates it has been about 48% less volatile than the market over the measured period, which is atypical for a high-growth pharmaceutical stock and may reflect its massive market cap and defensive characteristics during the observed timeframe.
Beta
0.52
0.52x market volatility
Max Drawdown
-23.6%
Largest decline past year
52-Week Range
$624-$1183
Price range past year
Annual Return
+43.7%
Cumulative gain past year
| Period | LLY Return | S&P 500 |
|---|---|---|
| 1m | +4.0% | -1.6% |
| 3m | +20.8% | +11.7% |
| 6m | +2.8% | +6.3% |
| 1y | +43.7% | +22.2% |
| ytd | +2.5% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LLY Fundamental Analysis
Eli Lilly is experiencing explosive revenue growth, driven primarily by its cardiometabolic franchise. For Q4 2025, revenue reached $19.29 billion, representing a staggering year-over-year growth rate of 42.56%. This acceleration is clear when examining the sequential quarterly revenue trend within 2025: Q1 at $12.73B, Q2 at $15.56B, Q3 at $17.60B, and Q4 at $19.29B. Segment data confirms the Cardiometabolic Health segment, which includes Mounjaro and Zepbound, is the primary engine, contributing $13.18 billion, while Oncology ($2.41B) and Immunology ($1.36B) provide additional growth vectors. Profitability is robust and margins are expanding significantly. Net income for Q4 2025 was $6.64 billion, resulting in a net margin of 34.40%. The gross margin of 85.05% is exceptionally high, typical for innovative pharmaceuticals, and has expanded from 82.54% in Q1 2025. Operating income was $8.78 billion, yielding an operating margin of 45.56%, which has also improved from 42.49% in Q1 2025. This margin expansion demonstrates the operating leverage the company is achieving as it scales its blockbuster products. The balance sheet is leveraged but supported by immense cash generation. The debt-to-equity ratio is elevated at 1.60, reflecting strategic debt usage for growth initiatives. However, the company's return on equity is an extraordinary 77.78%, indicating highly efficient use of shareholder capital. Trailing twelve-month free cash flow is a substantial $8.97 billion, providing ample internal funding for R&D, dividends ($1.35B paid in Q4), and share repurchases ($1.51B in Q4). The current ratio of 1.58 indicates sufficient short-term liquidity to meet obligations.
Quarterly Revenue
$19.3B
2025-12
Revenue YoY Growth
+0.42%
YoY Comparison
Gross Margin
+0.85%
Latest Quarter
Free Cash Flow
$9.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LLY Overvalued?
Given the company's substantial positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 46.76x, while the forward PE is 24.69x, based on estimated EPS of $63.81. The significant gap between trailing and forward multiples implies the market is pricing in a near-doubling of earnings, reflecting high confidence in the growth trajectory from its obesity and diabetes drugs. Compared to industry averages, Eli Lilly trades at a substantial premium. Its trailing PE of 46.76x and forward PE of 24.69x are well above typical large-cap pharmaceutical averages, which often range in the mid-teens to low-20s. This premium is justified by the company's superior growth profile, with revenue growth exceeding 40% YoY, compared to the low-to-mid single-digit growth typical of the sector, and its leadership in the high-margin, high-growth GLP-1 market. Historically, the current valuation is near the upper end of its own range. The historical ratios data shows the PE ratio has fluctuated widely, from 29.13x in March 2023 to over 67x in March 2025. The current trailing PE of 46.76x sits above the median of this recent historical range, indicating the market is pricing in optimistic expectations for sustained blockbuster performance. Trading near historical highs suggests little room for multiple expansion and increases sensitivity to any growth disappointments.
PE
46.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -2221x~206x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
35.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Eli Lilly's primary financial risk is its extreme dependence on the cardiometabolic franchise, which constituted 68% of Q4 2025 revenue ($13.18B of $19.29B). While margins are expanding (gross margin 85.05%), the company carries elevated financial leverage with a debt-to-equity ratio of 1.60. Although robust free cash flow ($8.97B TTM) currently services this debt, any slowdown in the growth trajectory of Mounjaro and Zepbound—the engines of its 42.56% YoY revenue surge—could quickly pressure earnings and call the valuation into question. The company's entire investment thesis is predicated on maintaining this exceptional growth rate to justify its premium multiples.
Market & Competitive Risks: The most significant external threat is intensifying competition in the obesity/diabetes market, as highlighted by recent news of Pfizer's promising monthly-injection drug and Novo Nordisk's Wegovy pill success. Eli Lilly trades at a substantial valuation premium (forward PE 24.69x vs. sector median likely in the teens), making it highly susceptible to multiple compression if it loses its perceived growth advantage. Furthermore, the stock's beta of 0.517 suggests it has been less volatile than the market, but this atypical stability for a growth stock could reverse if the narrative shifts, leading to a violent derating. Regulatory and pricing pressures, as seen with Novo Nordisk's Wegovy pill priced at $149, represent additional headwinds.
Worst-Case Scenario: The worst-case scenario involves a combination of competitive market share loss, pricing pressure, and a growth deceleration that triggers a severe valuation derating. This could be catalyzed by a superior competing drug launch or disappointing clinical trial results for Lilly's pipeline candidates. In this adverse scenario, the stock could realistically re-test its 52-week low of $623.78, representing a downside of approximately -43% from the current price of ~$1,099. A more immediate bear-case target, aligned with the low analyst EPS estimate, suggests a floor near $1,470 (using $59.54 EPS and a compressed forward multiple of 24.69x), still implying a -25% downside if growth expectations are materially reset.
FAQ
The key risks, in order of severity, are: 1) Competitive: Erosion of market share and pricing power in its core GLP-1 business from rivals like Novo Nordisk and Pfizer. 2) Valuation: A sharp multiple compression if growth decelerates, given its high trailing PE of 46.76x. 3) Financial: Elevated debt-to-equity of 1.60, though currently well-supported by cash flow. 4) Concentration: Over 68% of revenue from the Cardiometabolic segment, creating dependency on a single product category. Any negative development in this area would have an outsized impact.
The 12-month forecast presents three scenarios. The base case (50% probability) targets $1,470-$1,575, aligning with analyst consensus and assuming strong but moderating growth. The bull case (30% probability) targets $1,716+, requiring flawless execution and no competitive setbacks. The bear case (20% probability) sees a drop to the $623-$1,200 range if competition severely disrupts the growth narrative. The most likely outcome is the base case, where earnings growth drives returns but multiple expansion is limited. The key assumption is that Lilly maintains its leadership position despite increasing competition.
LLY is fairly valued relative to its own explosive growth trajectory but overvalued compared to the broader pharmaceutical sector. Its trailing PE of 46.76x and forward PE of 24.69x command a large premium over typical large-cap pharma multiples in the teens. This premium is justified by its 42.56% YoY revenue growth versus sector median growth in low single digits. The valuation implies the market expects near-perfect execution and sustained hyper-growth for several years to come, leaving little room for disappointment.
LLY is a good buy for investors who believe its dominance in the obesity/diabetes drug market is durable and can justify its premium valuation (forward PE 24.69x). The stock offers significant potential upside (~43% to analyst targets) but carries high risk from intensifying competition and valuation sensitivity. It is a good buy for long-term, growth-focused investors comfortable with volatility, but a less ideal choice for conservative investors or those seeking immediate value. The current price near 52-week highs suggests waiting for a pullback might improve the risk/reward profile.
LLY is primarily suitable for a long-term investment horizon (3-5 years minimum). Its thesis is based on the multi-year commercialization of its obesity/diabetes franchise and pipeline development, not short-term trading catalysts. While the stock has a beta of 0.517, indicating lower historical volatility, its premium valuation and news-driven nature around clinical trials make it prone to sharp swings, as seen in its -23.64% maximum drawdown. Short-term traders face significant headline risk. Long-term investors can better weather volatility and benefit from the underlying growth of a transformative therapeutic market.